Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
102.1 SEK | +1.69% | +0.20% | -19.59% |
Sales 2023 | 1.21B 111M | Sales 2024 * | 1.94B 179M | Capitalization | 5.39B 497M |
---|---|---|---|---|---|
Net income 2023 | -466M -42.99M | Net income 2024 * | 85M 7.84M | EV / Sales 2023 | 5.65 x |
Net cash position 2023 | 7.14M 658K | Net cash position 2024 * | 125M 11.53M | EV / Sales 2024 * | 2.72 x |
P/E ratio 2023 |
-14.6
x | P/E ratio 2024 * |
23.7
x | Employees | 181 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 73.29% |
Latest transcript on Calliditas Therapeutics AB
1 day | +1.69% | ||
1 week | +0.20% | ||
Current month | -9.88% | ||
1 month | -11.36% | ||
3 months | -13.02% | ||
6 months | +8.09% | ||
Current year | -19.59% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 17-05-17 | |
Director of Finance/CFO | 47 | 17-07-31 | |
Chief Tech/Sci/R&D Officer | 60 | 20-07-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Driscoll
BRD | Director/Board Member | 73 | 23-05-29 |
Henrik Stenqvist
BRD | Director/Board Member | 57 | 21-12-31 |
Elmar Schnee
CHM | Chairman | 65 | 19-05-07 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - | |
0.00% | 1 M€ | -.--% | - | |
0.00% | 29 M€ | -2.71% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 102.2 | +1.79% | 31 904 |
24-04-24 | 100.4 | 0.00% | 123,026 |
24-04-23 | 100.4 | +0.10% | 85,841 |
24-04-22 | 100.3 | -0.20% | 108,878 |
24-04-19 | 100.5 | -1.47% | 67,039 |
Delayed Quote Nasdaq Stockholm, April 25, 2024 at 05:19 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.59% | 495M | |
+4.51% | 70.78B | |
+10.72% | 9.15B | |
-15.34% | 4.84B | |
+34.54% | 4.22B | |
+5.09% | 3.92B | |
+23.79% | 2.55B | |
-28.33% | 2.24B | |
-24.15% | 2.26B | |
+6.23% | 1.92B |
- Stock Market
- Equities
- CALTX Stock